Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson Test for Antibiotic-Resistant Bacteria Cleared by FDA

NEW YORK (360Dx) – BD announced today that the US Food and Drug Administration has cleared the BD Phoenix CPO test, which could help hospitals contain the spread of antimicrobial resistance by shortening the time to detect carbapenemase-producing organisms.

The test, BD said, helps in identifying infections caused by CPOs, allowing hospitals to implement infection control procedures and begin appropriate antibiotic therapies more quickly. The test is available in two configurations as part of the BD Phoenix automated microbiology system and can provide the Ambler classification of the enzyme produced to aid in therapy decision-making.

It is included on BD Phoenix gram-negative panels, and it streamlines laboratory workflow "by routine, concurrent testing of CPO and susceptibility to one panel," Franklin Lakes, New Jersey-based BD said in a statement, adding The BD Phoenix CPO test can detect CPOs in less than 36 hours compared to up to 96 hours with conventional phenotypic methods for CPO detection.

All version of the test will be available starting in January, BD said.

"The BD Phoenix CPO detect test gives laboratories an accurate and cost-effective method to rapidly identify CPOs and support patient management," said Steve Conly, vice president, general manager of microbiology for BD Diagnostic Systems.